Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guilonghulou
- Development stage
- Preclinical
- Lead developer
- Reckitt
- Administration
- Topical
01
Overview
Guilonghulou is a coating agent investigated for the prevention and treatment of thrombosis in autologous arteriovenous fistula in hemodialysis patients. It appears to be a proprietary Chinese medicine formulation, likely developed as a topical or local application to vascular access sites to reduce the risk of clot formation. The precise mechanism of action, active ingredients, and pharmacological class are not specified in available sources. Its use is being studied primarily within the context of traditional Chinese medicine approaches for vascular protection and thrombosis prevention[1].
- Other names
- Guilonghulou Coating Agent
Beyond the preview
Go deeper on Guilonghulou.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guilonghulou.